ProCE Banner Activity

19-28ζ CAR T-Cells Induce High CR Rate in Relapsed/Refractory Adult ALL

Slideset Download
Conference Coverage
CD19-targeted 19-28ζ CAR T-cell therapy produced a high CR rate in adult patients with relapsed/refractory ALL.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation